(1-methyl-2-pyrrolidinyl)(phenyl)methanone O-benzyloxime | 850265-14-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1-methyl-2-pyrrolidinyl)(phenyl)methanone O-benzyloxime
• 英文别名: (1-Methyl-2-pyrrolidinyl)(phenyl)methanone O-benzyloxime；1-(1-methylpyrrolidin-2-yl)-1-phenyl-N-phenylmethoxymethanimine
• CAS: 850265-14-4
• 化学式: C₁₉H₂₂N₂O
• 分子量: 294.396
• InChiKey: NNLDYVMLIJOGQJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  24.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1-methyl-2-pyrrolidinyl)(phenyl)methanone O-benzyloxime 在 palladium 10% on activated carbon 盐酸 、 氢气 、 氨 作用下， 以 乙醇 、 水 、 二氯甲烷 为溶剂， 反应 8.0h， 生成 [(1-methyl-2-pyrrolidinyl)phenyl]methylamine
  参考文献：
  名称：

  Derivatives of N-[phenyl(pyrrolidine-2-yl)methyl]benzamide and N-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics

  摘要：

  本文所定义的式（I）的化合物：对治疗与痴呆、精神病有关的行为障碍，尤其是精神分裂症（缺乏型和产生型）以及由神经类药物引起的急性或慢性锥体外症状有用；用于治疗各种形式的焦虑、惊恐发作、恐惧症和强迫性强迫症；用于治疗各种形式的抑郁症，包括精神病性抑郁症；用于治疗由酒精滥用或戒酒引起的障碍、性行为障碍、饮食障碍以及治疗偏头痛。此外，该发明的化合物可用于治疗风湿病学中的疼痛性肌肉痉挛和急性脊柱病理学；用于治疗髓性或脑性起源的痉挛性痉挛；用于轻度到中度强度的急性和亚急性疼痛的症状性治疗；用于治疗剧烈和/或慢性疼痛、神经性疼痛和难治性疼痛；用于治疗帕金森病和由神经退行性起源或神经类药物引起的帕金森样症状；用于治疗简单或复杂症状学、混合形式和其他癫痫综合征的部分原发性和继发性广泛发作，除了另一种抗癫痫治疗之外，或单独治疗，用于治疗睡眠呼吸暂停和神经保护。

  公开号：

  US20060223802A1
• 作为产物：
  描述：

  聚合甲醛 、 phenyl(2-pyrrolidinyl)methanone O-benzyloxime 以 mixture ( 1/1 ) 、 甲酸 为溶剂， 反应 16.0h， 生成 (1-methyl-2-pyrrolidinyl)(phenyl)methanone O-benzyloxime
  参考文献：
  名称：

  Derivatives of N-[phenyl(pyrrolidine-2-YL)methyl]benzamide and N-[(azepan-2-YL) phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics

  摘要：

  本发明所定义的式（I）的化合物：可用于治疗与痴呆、精神病有关的行为障碍，特别是精神分裂症（缺陷型和生产型）和神经阻滞剂引起的急性或慢性锥体外症状；用于治疗各种形式的焦虑、惊恐发作、恐惧症和强迫性障碍；用于治疗各种形式的抑郁症，包括精神病性抑郁症；用于治疗由酒精滥用或戒酒引起的障碍，性行为障碍，饮食障碍以及治疗偏头痛。此外，本发明的化合物可用于治疗风湿病学中的疼痛性肌肉挛缩和急性脊柱病理学；用于治疗髓性或脑性起源的痉挛性挛缩；用于轻至中度强度的急性和亚急性疼痛的症状治疗；用于治疗剧烈和/或慢性疼痛，神经病性疼痛和难治性疼痛；用于治疗帕金森病和神经退行性起源或由神经阻滞剂引起的帕金森样症状；用于治疗简单或复杂症状的部分原发性和继发性广泛性癫痫，混合型和其他癫痫综合症以及其他抗癫痫治疗，或单独治疗，用于治疗睡眠呼吸暂停和神经保护。

  公开号：

  US07700585B2

文献信息

• DERIVATIVES OF N-[PHENYL(PYRROLIDINE-2-YL)METHYL]BENZAMIDE AND N-[(AZEPAN-2-YL)PHENYLMETHYL]BENZAMIDE, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS
  申请人：DARGAZANLI Gihad

  公开号：US20070208006A1

  公开（公告）日：2007-09-06

  Compounds of formula (I) as defined herein: are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic depression; for treating disorders caused by alcohol abuse or weaning from alcohol, sexual behavior disorders, eating disorders and for treating migraine. Moreover, the compounds of the invention may be used for treating painful muscle contracture in rheumatology and in acute spinal pathology; for treating spastic contractures of medullary or cerebral origin; for the symptomatic treatment of acute and subacute pain of light to moderate intensity; for treating intense and/or chronic pain, neurogenic pain and intractable pain; for treating Parkinson's disease and Parkinson-like symptoms of neurodegenerative origin or induced by neuroleptics; for treating partial primary and secondary generalized epilepsy of simple or complex symptomology, mixed forms and other epileptic syndromes in addition to another antiepileptic treatment, or in monotherapy, for the treatment of sleep apnea, and for neuroprotection.

  此处定义的化合物（I）的公式化合物，可用于治疗与痴呆症、精神病有关的行为障碍，尤其是精神分裂症（缺陷型和生产型）以及由神经类药物引起的急性或慢性锥体外症状；用于治疗各种形式的焦虑、惊恐发作、恐惧症和强迫性障碍；用于治疗各种形式的抑郁症，包括精神病性抑郁症；用于治疗由酗酒或戒酒引起的障碍、性行为障碍、进食障碍以及偏头痛；此外，该发明的化合物可用于治疗风湿病中疼痛的肌肉痉挛和急性脊柱病理学；用于治疗髓性或脑性起源的痉挛性收缩；用于轻至中度强度的急性和亚急性疼痛的症状性治疗；用于治疗强烈和/或慢性疼痛、神经源性疼痛和难治性疼痛；用于治疗帕金森病和神经退行性起源或神经类药物引起的帕金森样症状；用于治疗简单或复杂症状学、混合型和其他癫痫综合症的部分原发性和继发性广泛性癫痫，除了另一种抗癫痫治疗外，或单独用于治疗睡眠呼吸暂停，并用于神经保护。
• Derivatives of N-[phenyl(pyrrolidine-2-yl)methyl]benzamide and N-[(azepan-2-yl)phenylmethyl]benzamide, preparation, and use in treatment of schizophrenia
  申请人：Sanofi-Aventis

  公开号：US07226917B2

  公开（公告）日：2007-06-05

  Compounds of formula (I) as defined herein: are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic depression; for treating disorders caused by alcohol abuse or weaning from alcohol, sexual behavior disorders, eating disorders and for treating migraine.

  本文所定义的化合物公式(I)可用于治疗与痴呆、精神病、特别是精神分裂症（缺陷型和产生型）以及由神经类药物引起的急性或慢性锥体外症状有关的行为障碍；用于治疗各种形式的焦虑、惊恐发作、恐惧症和强迫性神经症；用于治疗各种形式的抑郁症，包括精神性抑郁症；用于治疗由酒精滥用或戒酒引起的障碍、性行为障碍、进食障碍以及偏头痛。
• Derivatives of N-[phenyl(pyrrolidine-2-yl)methyl]benzamide and N-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics
  申请人：Dargazanli Gihad

  公开号：US20060223802A1

  公开（公告）日：2006-10-05

  Compounds of formula (I) as defined herein: are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic depression; for treating disorders caused by alcohol abuse or weaning from alcohol, sexual behavior disorders, eating disorders and for treating migraine. Moreover, the compounds of the invention may be used for treating painful muscle contracture in rheumatology and in acute spinal pathology; for treating spastic contractures of medullary or cerebral origin; for the symptomatic treatment of acute and subacute pain of light to moderate intensity; for treating intense and/or chronic pain, neurogenic pain and intractable pain; for treating Parkinson's disease and Parkinson-like symptoms of neurodegenerative origin or induced by neuroleptics; for treating partial primary and secondary generalized epilepsy of simple or complex symptomology, mixed forms and other epileptic syndromes in addition to another antiepileptic treatment, or in monotherapy, for the treatment of sleep apnea, and for neuroprotection.

  本文所定义的式（I）的化合物：对治疗与痴呆、精神病有关的行为障碍，尤其是精神分裂症（缺乏型和产生型）以及由神经类药物引起的急性或慢性锥体外症状有用；用于治疗各种形式的焦虑、惊恐发作、恐惧症和强迫性强迫症；用于治疗各种形式的抑郁症，包括精神病性抑郁症；用于治疗由酒精滥用或戒酒引起的障碍、性行为障碍、饮食障碍以及治疗偏头痛。此外，该发明的化合物可用于治疗风湿病学中的疼痛性肌肉痉挛和急性脊柱病理学；用于治疗髓性或脑性起源的痉挛性痉挛；用于轻度到中度强度的急性和亚急性疼痛的症状性治疗；用于治疗剧烈和/或慢性疼痛、神经性疼痛和难治性疼痛；用于治疗帕金森病和由神经退行性起源或神经类药物引起的帕金森样症状；用于治疗简单或复杂症状学、混合形式和其他癫痫综合征的部分原发性和继发性广泛发作，除了另一种抗癫痫治疗之外，或单独治疗，用于治疗睡眠呼吸暂停和神经保护。
• Derivatives of N-[phenyl(pyrrolidine-2-YL)methyl]benzamide and N-[(azepan-2-YL) phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics
  申请人：sanofi-aventis

  公开号：US07700585B2

  公开（公告）日：2010-04-20

  Compounds of formula (I) as defined herein: are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic depression; for treating disorders caused by alcohol abuse or weaning from alcohol, sexual behavior disorders, eating disorders and for treating migraine. Moreover, the compounds of the invention may be used for treating painful muscle contracture in rheumatology and in acute spinal pathology; for treating spastic contractures of medullary or cerebral origin; for the symptomatic treatment of acute and subacute pain of light to moderate intensity; for treating intense and/or chronic pain, neurogenic pain and intractable pain; for treating Parkinson's disease and Parkinson-like symptoms of neurodegenerative origin or induced by neuroleptics; for treating partial primary and secondary generalized epilepsy of simple or complex symptomology, mixed forms and other epileptic syndromes in addition to another antiepileptic treatment, or in monotherapy, for the treatment of sleep apnea, and for neuroprotection.

  本发明所定义的式（I）的化合物：可用于治疗与痴呆、精神病有关的行为障碍，特别是精神分裂症（缺陷型和生产型）和神经阻滞剂引起的急性或慢性锥体外症状；用于治疗各种形式的焦虑、惊恐发作、恐惧症和强迫性障碍；用于治疗各种形式的抑郁症，包括精神病性抑郁症；用于治疗由酒精滥用或戒酒引起的障碍，性行为障碍，饮食障碍以及治疗偏头痛。此外，本发明的化合物可用于治疗风湿病学中的疼痛性肌肉挛缩和急性脊柱病理学；用于治疗髓性或脑性起源的痉挛性挛缩；用于轻至中度强度的急性和亚急性疼痛的症状治疗；用于治疗剧烈和/或慢性疼痛，神经病性疼痛和难治性疼痛；用于治疗帕金森病和神经退行性起源或由神经阻滞剂引起的帕金森样症状；用于治疗简单或复杂症状的部分原发性和继发性广泛性癫痫，混合型和其他癫痫综合症以及其他抗癫痫治疗，或单独治疗，用于治疗睡眠呼吸暂停和神经保护。